Dataset Information

Yoga and the experience of embodiment: a discussion of possible links.

ABSTRACT: The impact of yoga on body image and embodiment has been a recent area of focus in the field of body image and eating disorders. This paper comprises a theoretical discussion of how the practice of yoga can lead to positive ways of inhabiting the body, specifically through the lens of the Developmental Theory of Embodiment. Yoga may enhance the overall experience of embodiment, by having a positive impact on each of its five dimensions: body connection and comfort, agency and functionality, attuned self-care, subjective immersion (resisting objectification), and experience and expression of desires. The article therefore describes examples of teacher-related practices during yoga that can enhance each of these dimensions. Further, yoga teachers can consider the varied protective physical and social factors delineated by the Developmental Theory of Embodiment to facilitate positive embodiment. Future research should explicitly integrate embodiment theory with yoga interventions, as well as measures that assess both possible mechanisms of change and positive ways of living in the body.

SUBMITTER: Piran N

PROVIDER: S-EPMC7347427 | biostudies-literature | 2020 Jul-Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Yoga and the experience of embodiment: a discussion of possible links.

Piran Niva N Neumark-Sztainer Dianne D

Eating disorders 20200110 4

The impact of yoga on body image and embodiment has been a recent area of focus in the field of body image and eating disorders. This paper comprises a theoretical discussion of how the practice of yoga can lead to positive ways of inhabiting the body, specifically through the lens of the Developmental Theory of Embodiment. Yoga may enhance the overall experience of embodiment, by having a positive impact on each of its five dimensions: body connection and comfort, agency and functionality, attu ...[more]

PMID: 31922924

Similar Datasets

Project description:BackgroundCarfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. Although cardiopulmonary and vascular events have been reported infrequently, they can be potentially serious complications, and their incidence and pathophysiology following carfilzomib treatment remain poorly characterized in a real-world patient population.MethodsWe retrospectively reviewed the records of 67 patients with relapsed and/or refractory multiple myeloma treated at our institution.ResultsWe describe 12 patients who experienced cardiac or vascular-related adverse events subsequent to carfilzomib-based treatment (median age, 59 years [range, 49-77]). Nine patients had prior autologous stem cell transplant, and three had prior anthracycline exposure. Detailed case reports are provided for five representative patients: (1) systemic hypertension in a 65-year-old Caucasian female with a history of hypertension, hypothyroidism, and stage III chronic kidney disease; (2) pulmonary hypertension in a 72-year-old Caucasian male with a history of recurrent respiratory infections and chronic right lower extremity deep venous thrombosis; (3) acute renal insufficiency with increased blood pressure in a 50-year-old Caucasian male with a history of hypertension and stage IV chronic kidney disease; (4) heart failure in a 64-year-old African American female with a history of hypertension; and (5) dyspnea and lung disease in a 58-year-old Asian American male with a history significant for hepatitis B virus infection.ConclusionsWhile cardiac and vascular-related adverse events were reported in patients with relapsed and/or refractory multiple myeloma who were treated with carfilzomib, most patients had a history of the specific cardiac or vascular adverse event they exhibited and demonstrated an improvement or resolution in symptoms after the discontinuation of therapy. Appropriate screening and monitoring could potentially allow at-risk patients to benefit fully from treatment with carfilzomib.

Project description:BackgroundBesides anti-inflammatory medication, physical exercise represents a cornerstone of modern treatment for patients with axial spondyloarthritis (AS). Digital health apps (DHAs) such as the yoga app YogiTherapy could remotely empower patients to autonomously and correctly perform exercises.ObjectiveThis study aimed to design and develop a smartphone-based app, YogiTherapy, for patients with AS. To gain additional insights into the usability of the graphical user interface (GUI) for further development of the app, this study focused exclusively on evaluating users' interaction with the GUI.MethodsThe development of the app and the user experience study took place between October 2020 and March 2021. The DHA was designed by engineering students, rheumatologists, and patients with AS. After the initial development process, a pilot version of the app was evaluated by 5 patients and 5 rheumatologists. The participants had to interact with the app's GUI and complete 5 navigation tasks within the app. Subsequently, the completion rate and experience questionnaire (attractiveness, perspicuity, efficiency, dependability, stimulation, and novelty) were completed by the patients.ResultsThe results of the posttest questionnaires showed that most patients were already familiar with digital apps (4/5, 80%). The task completion rates of the usability test were 100% (5/5) for the tasks T1 and T2, which included selecting and starting a yoga lesson and navigating to an information page. Rheumatologists indicated that they were even more experienced with digital devices (2/5, 40% experts; 3/5, 60% intermediates). In this case, they scored task completion rates of 100% (5/5) for all 5 usability tasks T1 to T5. The mean results from the User Experience Questionnaire range from -3 (most negative) to +3 (most positive). According to rheumatologists' evaluations, attractiveness (mean 2.267, SD 0.401) and stimulation (mean 2.250, SD 0.354) achieved the best mean results compared with dependability (mean 2.000, SD 0.395). Patients rated attractiveness at a mean of 2.167 (SD 0.565) and stimulation at a mean of 1.950 (SD 0.873). The lowest mean score was reported for perspicuity (mean 1.250, SD 1.425).ConclusionsThe newly developed and tested DHA YogiTherapy demonstrated moderate usability among rheumatologists and patients with rheumatic diseases. The app can be used by patients with AS as a complementary treatment. The initial evaluation of the GUI identified significant usability problems that need to be addressed before the start of a clinical evaluation. Prospective trials are also needed in the second step to prove the clinical benefits of the app.

Dataset Information

Yoga and the experience of embodiment: a discussion of possible links.

Publications

Yoga and the experience of embodiment: a discussion of possible links.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets